Merck & Co., Inc. Deferred Income Tax Liabilities, Net
Merck & Co., Inc. (MRK) had Deferred Income Tax Liabilities, Net of $1.43 billion as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2026-08-07
- 2026-06-30: Deferred Income Tax Liabilities, Net $1.43B.
- 2026-03-31: Deferred Income Tax Liabilities, Net $1.49B.
- 2025-12-31: Deferred Income Tax Liabilities, Net $1.44B.
- 2025-09-30: Deferred Income Tax Liabilities, Net $1.38B.
| Period end | Deferred Income Tax Liabilities, Net | Deferred Income Tax Liabilities, Net as first filed |
|---|---|---|
| 2026-06-30 | $1.43B 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $1.49B 10-Q · filed 2026-05-04 | |
| 2025-12-31 | $1.44B 10-Q · filed 2026-08-07 | |
| 2025-09-30 | $1.38B 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $1.43B 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $1.41B 10-Q · filed 2025-05-02 | |
| 2024-12-31 | $1.39B 10-K · filed 2026-02-24 | |
| 2024-09-30 | $864.00M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $876.00M 10-Q · filed 2024-08-05 | |
| 2024-03-31 | $922.00M 10-Q · filed 2024-05-03 | |
| 2023-12-31 | $871.00M 10-K · filed 2025-02-25 | |
| 2023-09-30 | $1.02B 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $996.00M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $1.44B 10-Q · filed 2023-05-05 | |
| 2022-12-31 | $1.79B 10-K · filed 2024-02-26 | |
| 2022-09-30 | $2.42B 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $2.97B 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $3.07B 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $3.44B 10-K · filed 2023-02-24 | |
| 2021-09-30 | $1.53B 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $1.49B 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $1.20B 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $1.00B 10-K · filed 2022-02-25 | $1.01B 10-K · filed 2021-02-25 |
| 2020-09-30 | $1.78B 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $2.09B 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $1.94B 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $1.47B 10-K · filed 2021-02-25 | |
| 2019-09-30 | $1.96B 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $2.09B 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $1.83B 10-Q · filed 2019-05-08 | |
| 2018-12-31 | $1.70B 10-K · filed 2020-02-26 | |
| 2018-09-30 | $2.06B 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $2.16B 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $2.21B 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $2.22B 10-K · filed 2019-02-27 | |
| 2016-12-31 | $5.08B 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |